期刊文献+

左心疾病相关肺动脉高压的临床诊治进展 被引量:8

Left heart disease-associated pulmonary hypertension: advances in its diagnosis and treatment
下载PDF
导出
摘要 左心疾病( LHD)不仅是导致心力衰竭的临床常见疾病,也是临床常见的导致肺动脉高压(PH)的病因之一.临床流行病学研究提示,LHD相关PH是PH最常见疾病类型之一,PH是LHD患者预后重要的预测因素之一,合并PH的LHD患者预后不良.超声心动图检查是目前临床常用的筛查LHD相关PH的无创性检查方法,同时对于LHD相关PH患者的基础疾病的诊断与病情评估也具有重要作用.LHD相关PH患者典型的血流动力学改变特点为毛细血管后PH.对于疑似LHD相关PH患者进行包括肺毛细血管楔压(PCWP)、肺动脉压力(PAP)、肺血管阻力(PVR)以及跨肺压梯度( mPAP - mPCWP)等血流动力学参数的血流动力学评估,具有重要的临床诊断、鉴别诊断、疾病评估和治疗决策作用.LHD相关PH的治疗首先应进行LHD基础疾病的优化治疗.虽然缺乏大型临床试验和循证医学的证据支持,治疗动脉型肺动脉高压有效的PH靶向治疗药物也被初步应用于部分LHD相关PH患者的治疗.LHD相关PH研究领域可能是目前及今后PH研究领域的热点和难点之一,也可能是目前及今后心力衰竭研究领域的热点之一. Left heart disease (LHD) is one of the most common causes of heart failure. Pulmonary hypertension (PH) is a common hemodynamic finding in patients with LHD and is usually associated with increased morbidity and mortality. LHD-assoicated PH is one of the most common types. Doppler echocardiography remains the most useful noninvasive tool for assessing the presence of PH in patients with LHD, and for diagnosis and assessment of LHD. Typical hemodynamic finding in LHD-associated PH is pre-capillary PH. Hemodynamic parameters, including pulmonary capillary wedge pressure, pulmonary artery pressure, pulmonary vascular resistance and transpulmonary pressure gradient (for example mPAP-mPCWP), are all valuable in diagnosis, differential diagnosis, assessment, and effective treatment of LHD-associated PH. Most importantly, the underlying cause of LHD should be treated firstly. Drugs with proven efficacy in pulmonary arterial hypertension are being increasingly used in LHD-associated PH, despite the virtual absence of supporting evidence from clinical trials. LHD-associated PH may be the hot and difficult point in the future researches on PH, as well as heart failure.
出处 《中华老年多器官疾病杂志》 2012年第1期69-73,共5页 Chinese Journal of Multiple Organ Diseases in the Elderly
基金 国家十一五科技攻关计划(2006BA101A070)
关键词 肺动脉高压 心力衰竭 诊断 治疗 pulmonary hypertension heart failure diagnosis treatment
  • 相关文献

参考文献1

二级参考文献33

  • 1Jukka Takala.Pulmonary capillary pressure[J]. Intensive Care Medicine . 2003 (6)
  • 2Champion HC,Michelakis ED,Hassoun PM.Comprehen- sive invasive and noninvasive approach to the right ventricle- pulmonary circulation unit: state of the art and clinical and research implications. Circulation . 2009
  • 3Naeije R,Huez S.Right ventricular function in pulmonary hy- pertension: physiological concepts. European Heart Journal . 2007
  • 4Soto FJ,Kleczka JF.Cardiopulmonary hemodynamics in pulmonary hypertension: pressure tracings, waveforms, and more. Adv Pulm Hypertension . 2008
  • 5Barberà JA,Escribano P,Morales P,Gómez MA,Oribe M,Martínez A,Román A,Segovia J,Santos F,Subirana MT.[Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Tho- racic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)]. Revista Espanola de Cardiologia . 2008
  • 6Tanabe N,Okada O,Abe Y,Masuda M,Nakajima N,Kuri- yama T.The influence of fractional pulse pressure on the out- come of pulmonary thromboendarterectomy. European Respiratory Journal . 2001
  • 7Nakayama Y,Nakanishi N,Sugimachi M,Takaki H,Kyotani S,Satoh T,Okano Y,Kunieda T,Sunagawa K.Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmo- nary hypertension. Journal of the American College of Cardiology . 1997
  • 8Badesch DB,Champion HC,Sanchez MA,Hoeper MM,Loyd JE,Manes A,McGoon M,Naeije R,Olschewski H,Oudiz RJ,Torbicki A.Diagnosis and assessment of pulmo- nary arterial hypertension. Journal of the American College of Cardiology . 2009
  • 9Grignola J,Devera L,Ginés F.Main pulmonary artery pres- sure waveform analysis: a time-domain approach for com- plete hemodynamic evaluation during pulmonary hyperten- sion. Circulation . 2008
  • 10Grant BJ,Lieber BB.Clinical significance of pulmonary arte- rial input impedance. European Respiratory Journal . 1996

共引文献4

同被引文献113

  • 1赵雪燕,杨跃进,张健,党爱民,倪新海,黄洁,康晟,马卫华,赵冬云.B型利钠肽在诊断左心衰竭中的价值[J].中华医学杂志,2006,86(17):1165-1169. 被引量:97
  • 2Yasumura Y. Combination of β-blocker and milrinone for acute heart fail- ure[ J]. Circ J,2012 ;76(7 ) : 1589-90.
  • 3Kobayashi S, Susa T, Tanaka T, et al. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus al- ternans in patients with acute decompensated heart failure [ J ]. Circ J, 2012 ;76(7 ) : 1646-53.
  • 4Guglin M, Khan H. Pulmonary hypertension in heart failure[J]. J Cardiac Fail,2010,16(6) :461 - 474.
  • 5Salloum FN,Abbate A, Das A, et al. Sildenafil(Viagra) attenu- ates ischemic cardiomyopathy and improves left ventricular func- tion in mice[J]. Am J Physiol Heart Circ Physioh2008,294(3) : HI398 - 406.
  • 6Escribano Subias P, Barbedt Mir JA, Suberviola V. Current diag- nostic andprognostic assessment of pulmonary hypertension [J]. Rev Esp Cardiol,2010,63(5):583-596.
  • 7Dai ZK,Wu BN,Chen IC, et al. Attenuation of pulmonary hyper- tension second - dary to left ventricular dysfunction in the rat by Rho - kinase in hibitor fasudil[J]. Pdiatr Pulmonol, 2011,46(1) : 45 - 59.
  • 8Chung HH,Dai ZK, Wu BN, et al. The xanthine derivative KMUP- 1 inhibits models of pulmonary artery hypertension via increased NO and cGMP- dependent inhibition of RhoA/Rho kinase[J]. Br J Pharmacoh2010,160(4) :971 - 986.
  • 9Ning Yin,Stephanie Kaestle,Jun Yin,Thomas Hentschel,Axel R. Pries,Hermann Kuppe,Wolfgang M. Kuebler.Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease[J]. Critical Care Medicine . 2009 (3)
  • 10Maya Guglin,Hammad Khan.Pulmonary Hypertension in Heart Failure[J]. Journal of Cardiac Failure . 2010 (6)

引证文献8

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部